New Study Suggests Lilly's Weight-Loss Drug May Cause More Lean Body Mass Loss
LLY sits 44% above its 52-week low of $623.78 on light trading volume (0.4× avg).
Summary
A new study published ahead of peer review suggests Eli Lilly's weight-loss drug tirzepatide (Zepbound/Mounjaro) may lead to greater loss of lean body mass compared to Novo Nordisk's semaglutide (Wegovy/Ozempic). The analysis found tirzepatide patients lost an average of 1.1% more lean body mass after three months and 2% after 12 months. This finding introduces a potential competitive disadvantage for Lilly's blockbuster GLP-1 drugs, as preserving lean body mass is a significant concern for patients and prescribers. While Lilly has recently seen positive developments for its weight-loss pipeline, this study could influence future prescribing patterns and market perception. Traders will be watching for further research and Lilly's official response to these findings.
At the time of this announcement, LLY was trading at $901.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $851.3B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.